Investors alerted to securities fraud investigation involving Jasper Therapeutics, Inc. (JSPR)

On September 23, 2025, Glancy Prongay & Murray LLP, a respected national law firm specializing in shareholder rights, announced that it had initiated an investigation into potential securities law violations by Jasper Therapeutics, Inc. (referred to as “Jasper” or the “Company”) (NASDAQ: JSPR) that may have impacted investors.

Jasper had released an update on July 7, 2025, regarding its Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of Chronic Spontaneous Urticaria (CSU), known as the “BEACON Study.” The update revealed that issues with one drug product lot had affected the study results for some patients, necessitating the return of the product and the cessation of dosing. Additionally, the Company announced the halting of various studies, including asthma and SCID, along with cost-cutting measures such as potential restructuring to reduce expenses.

Subsequently, Jasper’s stock price plummeted by 55.1% to $3.04 per share on the same day, causing financial losses to investors.

Glancy Prongay & Murray LLP advised affected investors to contact them to explore potential options to recover their losses or seek further information regarding this matter.

Persons possessing non-public information related to Jasper were encouraged to consider helping with the investigation or utilizing the SEC Whistleblower Program, offering rewards of up to 30% of any successful recovery.

Founded in 2004, Glancy Prongay & Murray LLP (GPM) has consistently represented investors and consumers across the country in securities and class action litigation. GPM has secured billions of dollars for its clients and has been recognized as a top law firm for securities class action settlements.

This press release serves as a notification to investors affected by the events concerning Jasper Therapeutics, Inc. In some jurisdictions under relevant laws, this press release is classified as Attorney Advertising.

For more information or assistance regarding this situation, interested parties are urged to get in touch with Glancy Prongay & Murray LLP.

Ultimately, the investigation into Jasper Therapeutics, Inc. highlights the firm’s commitment to holding companies accountable for potential securities law violations, signaling their dedication to safeguarding investor rights and interests.